BMS discontinues pair of IDO1, Opdivo combo trials

Bristol-Myers Squibb Co. (NYSE:BMY) discontinued two Phase III trials evaluating indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor BMS-986205 in combination with its PD-1 inhibitor Opdivo nivolumab, according to ClinicalTrials.gov. According to the website, the company cited that its "business objectives have changed."

One trial was evaluating the combination as first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) compared with Erbitux cetuximab, cisplatin/carboplatin and fluorouracil. The other trial was evaluating the combination with or without chemotherapy vs. chemotherapy alone in patients with previously untreated stage IV or recurrent non-small cell lung cancer (NSCLC)...